Comprehensive Laboratory Workup for Memory Loss
Order a complete metabolic panel, CBC, TSH, vitamin B12, and non-contrast brain MRI (or CT if MRI unavailable) as first-line tests for all patients presenting with new-onset memory loss. 1
Tier 1: Essential Initial Laboratory Tests
These tests must be ordered for every patient with memory loss to identify reversible causes:
Basic Metabolic Panel
- Complete metabolic panel including sodium, potassium, glucose, calcium, BUN, and creatinine 1, 2
- Glucose and sodium are the most frequent abnormalities requiring immediate intervention 2
- Hypoglycemia and hyponatremia are commonly missed metabolic causes that can fully reverse with treatment 3
Hematologic and Endocrine Testing
- Complete blood count (CBC) to evaluate for anemia and infection 1
- Thyroid-stimulating hormone (TSH) to exclude hypothyroidism, which mimics dementia presentation 1, 4
- Vitamin B12 levels as deficiency causes both cognitive impairment and peripheral neuropathy 1, 4
Hepatic and Renal Function
- Liver function tests (AST, ALT, bilirubin, albumin) 1
- Renal function (BUN, creatinine) already included in metabolic panel 1
Essential Neuroimaging
- Non-contrast brain MRI is the preferred first-line imaging modality 1
- If MRI is contraindicated or unavailable, obtain non-contrast head CT 1, 2
- Neuroimaging identifies structural lesions (tumors, subdural hematomas), hydrocephalus, infarcts, and patterns of atrophy 1
Tier 2: Additional Tests Based on Clinical Context
Order these when specific clinical features suggest particular etiologies:
Enhanced B12 Assessment
- Methylmalonic acid and homocysteine should be ordered simultaneously with B12 levels, as they increase diagnostic sensitivity even when B12 is borderline-low 4
- This combination prevents missing B12 deficiency that presents with normal-range serum B12 4
Infection Screening (When Indicated)
- Urinalysis and urine culture in patients with altered mental status or fever 2
- Syphilis serology (RPR, FTA-ABS) in atypical presentations or high-risk populations 1
- HIV serology in appropriate clinical contexts 1
Inflammatory Markers
- Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) when autoimmune or inflammatory conditions are suspected 1
- Antithyroid antibodies (anti-TPO, anti-thyroglobulin) to rule out Hashimoto's encephalopathy in cases with elevated TSH or atypical features 1
Metabolic Refinement
- HbA1c in patients with suspected diabetes or to assess chronic glycemic control 1
- Lipid profile may be evaluated but has lower diagnostic yield for acute memory loss 1
Tier 3: Specialized Testing for Complex Cases
Reserve these for rapidly progressive dementia, early-onset (<65 years), or when initial workup is unrevealing:
Cerebrospinal Fluid Analysis
- Lumbar puncture with CSF analysis for rapidly progressive dementia, suspected autoimmune encephalitis, or CNS infection 1, 5, 6
- CSF studies should include cell count, protein, glucose, and consideration of autoimmune/paraneoplastic panels 5, 6
Advanced Neuroimaging
- FDG-PET or SPECT to evaluate metabolic patterns in complex cases 1
- Amyloid PET may be considered when Alzheimer's disease diagnosis remains uncertain after standard workup 1
Critical Pitfalls to Avoid
- Do not delay B12 replacement while awaiting test results if clinical suspicion is high—irreversible neurologic damage can occur 4
- Do not attribute cognitive symptoms to pre-existing dementia without investigating acute reversible causes like infection, metabolic derangements, or medication effects 2
- Do not miss hypoactive delirium, which is frequently mistaken for depression or dementia but represents a medical emergency requiring urgent evaluation 2
- Do not order extensive autoimmune panels routinely—reserve these for rapidly progressive cases or when clinical features suggest autoimmune etiology 5, 6
Special Populations
- Patients with Down syndrome: Prioritize thyroid function testing due to higher prevalence of hypothyroidism 1
- Rapidly progressive dementia (<2 years): Expand workup to include CSF analysis, autoimmune/paraneoplastic panels, and consideration of prion disease 5, 6
- Young-onset dementia (<65 years): Lower threshold for lumbar puncture and advanced neuroimaging 1